Bavarian Nordic
Challenges in Moving Pharmaceutical Manufacturing to the US
Bavarian Nordic, pharmaceutical manufacturing, US relocation, time constraints, infrastructure limitations
Bavarian Nordic’s Vimkunya Approved by FDA as First Chikungunya Vaccine for Ages 12 and Up
Vimkunya, chikungunya vaccine, Bavarian Nordic, FDA approval, virus-like particle vaccine, adolescents, travelers
Bavarian Nordic Closes San Diego R&D Site, Lays Off 48 Employees
Bavarian Nordic, San Diego, R&D site closure, layoffs, pharmaceutical industry
Bavarian Nordic’s Mpox Vaccine Demonstrates Equivalent Efficacy in Teens and Adults: NIH Study
Mpox vaccine, Bavarian Nordic, MVA-BN vaccine, Teenagers, Adults, Antibody response, Safety, Efficacy, NIH study
WHO Prequalifies Bavarian Nordic’s MVA-BN Vaccine as First Mpox Vaccine
WHO, mpox vaccine, Bavarian Nordic, MVA-BN, prequalification, global health, vaccine access
Bavarian Nordic Shares Surge on Strong Earnings and Major Mpox Vaccine Order Amid Global Health Emergency
Bavarian Nordic, Mpox Vaccine, Global Health Emergency, WHO, Vaccine Order, Earnings Report
Bavarian Nordic Ramps Up Mpox Vaccine Production to Combat Global Health Emergency
Bavarian Nordic, Mpox Vaccine, Jynneos, Global Health Emergency, Africa CDC, WHO
Bavarian Nordic Returns to the Spotlight as Mpox Outbreak Reaches Emergency State
Bavarian Nordic, mpox outbreak, emergency state, vaccine production, WHO declaration, public health emergency